Review	Model to be used for Meta‐analysis
Aminobenzoate Potassium in the treatment of Raynaud's Phenomenon	Fixed effect
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for Raynaud's Phenomenon	Fixed effect
Anti‐Coagulation in the treatment of Raynaud's Phenomenon	Random effect
Anti‐Fungal Agents in the treatment of Raynaud's Phenomenon	Fixed effect
Calcitonin Gene Related Peptides in the treatment of Raynaud's Phenomenon	Fixed effect
Calcium channel blockers for Raynaud's phenomenon	Fixed effect
Cyclosporin A in the treatment of Raynaud's Phenomenon	Fixed effect
Dimethyl Sulfoxide in the treatment of Raynaud's Phenomenon	Fixed effect
Five hydroxytryptamine (5‐HT) /serotonin receptor drugs for the treatment of Raynaud's phenomenon (previously title ketanserin)	Fixed effect
Hexopal in the treatment of Raynaud's Phenomenon	Fixed effect
Hormones for Raynaud’s phenomenon (previously Cyclofenil)	Random effect
Ketotifen in the treatment of Raynaud's Phenomenon	Fixed effect
Nitrates in the treatment of Raynaud's Phenomenon	Fixed effect
PDE5 Inhibitors in the treatment of Raynaud's Phenomenon	Fixed effect
Plasma Exchange in the treatment of Raynaud's Phenomenon	Fixed effect
Prazosin and other alpha blockers for Raynaud's phenomenon	Fixed effect
Prostaglandins for Raynaud's phenomenon	Fixed effect
Buflomedil for Raynaud’s phenomenon	Fixed effect
Bosentan for Raynaud’s phenomenon	Fixed effect